( November 3, 2026, 9:58 AM EST) -- SAN ANTONIO — A Texas federal judge left intact the dismissal with prejudice of a compounding pharmacy’s antitrust claims against the manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications approved by the U.S. Food and Drug Administration, finding no manifest legal error in her conclusion that the pharmacy’s compounded GLP-1 drugs were not meaningful market alternatives to the manufacturers’ branded products....